Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30

$12.95−0.45 (-3.36%)

Close on Nov 12, 2026Market cap $908.68MP/E 323.8Yield –

Pharming ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2021 it was $19.95M, down 75.8% from the year before.

Period	Period end	Value	Change
FY2021	Dec 31, 2021	$19.95M	-75.8%
FY2020	Dec 31, 2020	$82.31M	+12.4%
FY2019	Dec 31, 2019	$73.24M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PHAR.

Revenue growth26.6% · median 38.4%

Gross margin87.9% · median 87.4%

Operating margin6.9% · median -63.0%

Net margin0.8% · median -44.9%

Advertisement
300 × 250

See a number that looks wrong?